

Creative Biolabs Highlights Ambitions on Non-IgG Therapeutic Antibody Development Service

A set of non-IgG therapeutic antibody development services, including antibody development services, antibody discovery services, and antibody developability improvement services, has been made accessible at Creative Biolabs to clients worldwide.

New York City, New York Oct 20, 2022 ([Issuewire.com](https://www.issuewire.com)) - It is now understood that the specificity of antibodies enables the precise targeting of specific antigens. Therapeutic antibodies are gaining popularity as a product with high hopes for good therapeutic outcomes and few side effects, and non-IgG antibodies are one of the most potent players among all types.

Powered by the Hyperdoma Platform, Phage Display Platform, Expression System Platform, and Antibody Engineering Platform, Creative Biolabs now introduces a set of therapeutic antibody development services for different [Non-IgG antibody isotypes](#), aiming at helping worldwide clients explore these bio-active molecules and create novel therapeutic agents.

The professional team is skilled at non-IgG therapeutic antibody discovery services, covering IgA, IgY, IgE, and [IgM antibodies](#), as a result of a wealth of expertise working with the antibody research community. Upon analyzing past cases, experts at Creative Biolabs can help clients get beyond challenges such as inadequate stability, lack of animal models, unstable protein A/G-binding, and limited solubility.

Another highlighted service is non-IgG therapeutic antibodies engineering, especially for IgA, IgM, and [IgE antibodies](#), containing optional non-IgG antibody engineering strategies to get better efficacy, covering humanization, half-life extension, glycosylation, conjugation, and isotype switching.

In addition, Creative Biolabs also provides PK/PD (pharmacokinetic/pharmacodynamics) evaluation services to boost the development of a manufacturable, stable, safe, and effective drug. The team can conduct PK/PD assays to analyze and evaluate therapeutic non-IgG antibodies immediately after they are produced, purified, and characterized. A wide range of animal models is available, including rodents, non-human primates, and dogs. The evaluation of PK/PD characteristics covers antibody absorption, binding, dose proportionality, distribution, targeting, metabolism, excretion, immunogenicity, translation PK/PD across species, and prediction of human PK/PD

The one-stop solutions also incorporate non-IgG therapeutic antibody production and purification, antibody characterization, and antibody developability improvement, covering the whole pipeline of antibody discovery. The rigorous testing and quality control standards mean that clients can always get the reliable and consistent results they need to execute research studies with confidence.

More information about services and products regarding non-IgG antibodies can be found on the official website: <https://non-igg-ab.creative-biolabs.com/>.

About Creative Biolabs

Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is skilled at providing non-IgG antibody development services with the support of the cutting-edge Antibody GlycoOptimize Platform and Expression System Platform. High-quality off-the-shelf non-IgG products (mainly IgA, IgM, and IgE monoclonal/polyclonal antibodies) and non-IgG antibody ELISA kits

are also available for both academic and commercial usage.

Media Contact

Creative Biolabs

marketing@creative-biolabs.com

Source : Creative Biolabs

[See on IssueWire](#)